Gosuranemab (powder) (Synonyms: BMS-986168 (powder); IPN007 (powder); BIIB092 (powder))

Cat. No.: HY-P99648A: Data Sheet
FAQs
Technical Support

Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease.

For research use only. We do not sell to patients.

Gosuranemab (powder) Chemical Structure

CAS No. : 1788032-39-2

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Gosuranemab (powder):

Gosuranemab

Other Forms of Gosuranemab (powder):

Gosuranemab In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Gosuranemab (powder) exhibits high binding affinity to monomeric and aggregated tau and removes seeding-competent tau from AD brain lysate^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Gosuranemab (powder) (murine version IPN002; weekly; 8 weeks) reduces unbound tau levels in the cerebrospinal fluid and interstitial fluid of rTg4510 tauopathy transgenic mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	rTg4510^[1]
Dosage:	murine version IPN002
Administration:	weekly; 8 weeks
Result:	Reduced levels of unbound tau in cerebrospinal fluid (CSF) and interstitial fluid (ISF) at 57 days post-treatment initiation.

CAS No.

1788032-39-2

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Dam T, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451-1457.

[2]. Shulman M, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease. Nat Aging. 2023;3(12):1591-1601.

Gosuranemab (powder) Related Classifications

Neurological Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Gosuranemab (powder)1788032-39-2BMS-986168 (powder) IPN007 (powder) BIIB092 (powder)Tau ProteinAD brain homogenatestotal tauextracellular N-terminal taurTg4510 tauopathy transgenic micephosphorylated tau181Alzheimer’s diseaseprogressive supranuclear palsytau PET SUVRblood-brain barriercerebrospinal fluidInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *